Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nutriband Provides Product Development Update for its Lead Product Aversa Fentanyl
Details : Aversa fentanyl abuse-deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, & accidental exposure of drugs.
Brand Name : Aversa Fentanyl
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 20, 2024
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nutriband Raises $8.4M for Aversa® Fentanyl Patch FDA Submission
Details : Net proceeds will fund the development of AVERSA Fentanyl, a potential first abuse-deterrent opioid patch to reduce misuse and accidental exposure risks with transdermal fentanyl.
Brand Name : Aversa Fentanyl
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 24, 2024
Nutriband Inc. Announces $8.4M Private Placement
Details : The primary use of proceeds will be for completing the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval.
Brand Name : Aversa Fentanyl
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 19, 2024
Nutriband Provides Overview for AVERSA(R) Fentanyl Transdermal Patch
Details : Aversa (fentanyl) utilizes abuse-deterrent transdermal technology with aversive agents to prevent drug abuse, diversion, and accidental exposure.
Brand Name : Aversa Fentanyl
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 27, 2024
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Kindeva Drug Delivery
Deal Size : Undisclosed
Deal Type : Agreement
Nutriband Signs Agreement with Kindeva for Abuse Deterrent Fentanyl Patch
Details : Kindeva will develop commercial manufacturing processes and clinical supplies for Aversa Fentanyl, integrating Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's fentanyl patch system.
Brand Name : Aversa Fentanyl
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2024
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Kindeva Drug Delivery
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Details : The net proceeds will be used to fund the development and regulatory submission process for the Company's patented lead product platform, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
Brand Name : Aversa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 14, 2023
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Kindeva Drug Delivery
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.
Brand Name : Aversa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 04, 2023
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Kindeva Drug Delivery
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing will be used for commercialising AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 28, 2023
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Aversa (fentanyl) abuse deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential such as opioids used to treat moderate to s...
Brand Name : Aversa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2022
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Aversa (fentanyl) is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.
Brand Name : Aversa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 01, 2022
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?